MANY MINDEDWeight-loss drugs show biological age slowing in overweight and diabetic patients
Eli Lilly and Novo Nordisk conducted clinical trials showing weight-loss drugs reduce biological age markers in overweight and diabetic patients. Their studies measured 10,052 participants (5,026 on drug, 5,026 placebo) using different aging clocks: Novo Nordisk employed proteomic clocks (protein levels), while Lilly used epigenetic clocks (DNA changes). Both companies observed an average biological age reduction of 2-3 years for patients taking GLP-1 drugs compared to placebo. Novo Nordisk's study specifically noted heart protein clocks showed maximum biological age reduction of 4 years. The findings were presented at an aging research conference and include Lilly's tirzepatide generating $36 billion in revenue last year.
The effect represents slowing of molecular aging markers—not reversal of aging—observed primarily in overweight or diabetic populations. Benefits vary by clock type and organ tested, with no single consistent magnitude across all measurements. Muscle loss is noted as a potential side effect. The ARPA-H study of semaglutide's effects on healthy people over 60 (launched January 2024) is ongoing and not yet complete.
This could reduce age-related disease burden for vulnerable populations by extending healthy lifespan and lowering healthcare costs for conditions linked to metabolic health. However, benefits remain limited to overweight/diabetic groups, and effects on healthy populations are unconfirmed. Muscle loss risks may also affect long-term feasibility for broader application.
What to watch: Completion of the ARPA-H study (2024 launch) and whether biological age reduction translates to actual health outcomes beyond molecular markers. Current evidence does not support claims of reversing aging or universal health benefits.
Source: MIT Tech Review